Home / Doxorubicin / Italy
IT ATC L01DB01 · updated 2 Nov 2026
Doxorubicin shortage in Italy
Is there a Doxorubicin shortage in Italy?
Yes. As of 2 Nov 2026, 10 Doxorubicin products are reported short in Italy, the first since 31 Aug 2023. No return date has been given. Main reason: manufacturing problem.
Also short in Canada, Germany, Ireland, Austria, Belgium, Czechia, Sweden. All countries.
Affected products in Italy
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| IT | DOXORUBICINA ACCORD HEALTHCARE ITALIA discontinuation | ACCORD HEALTHCARE, S.L.U. | 31 Aug 2023 | not given | Increased demand Elevata richiesta |
| IT | ZOLSKETIL PEGYLATED LIPOSOMAL discontinuation | ACCORD HEALTHCARE, S.L.U. | 27 Feb 2025 | not given | Manufacturing problem Problemi produttivi |
| IT | CAELYX PEGYLATED LIPOSOMAL discontinuation | BAXTER HOLDING BV | 8 Jun 2026 | not given | Manufacturing problem Problemi produttivi: distribuzione contingentata |
| IT | CAELYX PEGYLATED LIPOSOMAL discontinuation | BAXTER HOLDING BV | 8 Jun 2026 | not given | Manufacturing problem Problemi produttivi: distribuzione contingentata |
| IT | DOXORUBICINA ACCORD HEALTHCARE ITALIA discontinuation | ACCORD HEALTHCARE, S.L.U. | 30 Sep 2026 | not given | Commercial decision or withdrawal Motivi commerciali |
| IT | DOXORUBICINA ACCORD HEALTHCARE ITALIA discontinuation | ACCORD HEALTHCARE, S.L.U. | 1 Oct 2026 | not given | Commercial decision or withdrawal Motivi commerciali |
| IT | DOXORUBICINA AUROBINDO discontinuation | Eugia Pharma (Malta) Limited | 9 Oct 2026 | not given | Increased demand Elevata richiesta/problemi produttivi |
| IT | ADRIBLASTINA discontinuation | PFIZER ITALIA S.R.L. | 27 Oct 2026 | not given | Manufacturing problem Problemi produttivi |
| IT | ADRIBLASTINA anticipated discontinuation | PFIZER ITALIA S.R.L. | 10 Nov 2026 | not given | Manufacturing problem Problemi produttivi |
| IT | ADRIBLASTINA anticipated discontinuation | PFIZER ITALIA S.R.L. | 19 Jan 2027 | not given | Manufacturing problem Problemi produttivi |
Source
AIFA (Italian Medicines Agency), licensed CC-BY 4.0. Official list. All shortages reported by marketing-authorisation holders, including medicines being withdrawn.